trial · primary record
Durvalumab
Recurrent Lung Non-Small Cell Carcinoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2025-10-30 |
| Primary endpoint | Objective Response Rate (ORR) by RECIST v1.1 |
| Registry ID | NCT03581487 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:52.173Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03581487
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.